Accession Number: | 0001127602-21-025252 |
Date: | 2021-09-10 |
Issuer: | BIOCRYST PHARMACEUTICALS INC (BCRX) |
Original Submission Date: |
ABERCROMBIE GEORGE B
PO BOX 16069
CHAPEL HILL, NC 27516
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2021-09-10 | M | 11,000 | a | $1.71 | 14,000 | direct | ||
COMMON STOCK | 2021-09-10 | M | 30,000 | a | $3.22 | 44,000 | direct | ||
COMMON STOCK | 2021-09-10 | M | 30,000 | a | $2.91 | 74,000 | direct | ||
COMMON STOCK | 2021-09-10 | S | 74,000 | d | $15.09 | 0 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
AUTOMATIC STOCK OPTION GRANT | 1.71 | 2021-09-10 | deemed execution date | M | 11,000 (d) | 2013-06-30 | 2023-05-31 | common stock 11,000 | $1.71 | 0 | direct | |
AUTOMATIC STOCK OPTION GRANT | 3.22 | 2021-09-10 | deemed execution date | M | 30,000 (d) | 2016-06-23 | 2026-05-23 | common stock 30,000 | $3.22 | 0 | direct | |
AUTOMATIC STOCK OPTION GRANT | 2.91 | 2021-09-10 | deemed execution date | M | 30,000 (d) | 2020-05-29 | 2029-05-29 | common stock 30,000 | $2.91 | 0 | direct |
ID | footnote |
---|---|
f1 | the price in column 4 is a weighted average price. these shares were sold in multiple transactions ranging from $14.87 to $15.31. the reporting person will provide to the issuer, any security holder of the issuer, or the sec staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |